 |
ANCC Magnet/Pathway Conference, Chicago, IL
|
|
|
HANDOFF
|
Nurse Sues for Wegovy
|
Weight Loss drugs Wegovy and Ozempic are in high demand, but many employers and government programs won’t cover such costly obesity medications. A nurse in Washington is looking to change that. Jeannette Simonton’s insurance refused to pay for the much-needed medication, so she is suing the Washington State agency that purchases health insurance for public employees. The state recognizes obesity as a disability, so the state’s health plans are effectively discriminating against Simonton and others, her lawyers argue.
|
|
|
Unapproved Semaglutide Online
|
If you or your patients want a cheap version of Wegovy, be careful with online vendors. The FDA is warning two online vendors — Semaspace and Gorilla Healing — to stop selling unapproved versions of semaglutide and tirzepatide, the active ingredients in Wegovy. It’s unclear what issues people may suffer from taking these unapproved drugs. However, a recent study found that people who take Ozempic or Wegovy may be at an increased risk of severe stomach problems.
|
|
|
Ripple Effects of Weight Loss Drugs
|
The new weight loss drugs will undoubtedly affect the food industry by shifting what and how much people on the drugs eat. Walmart reported that people taking GLP-1 drugs like Wegovy buy slightly less food, while companies like Oreos and Ritz saw a dip in their stock. But investors think its effects
won’t stop there, affecting everything from which clothes people buy to how much they weigh down passenger planes. The drugs may even impact markets for tobacco, alcohol, and gaming, given that they reduce cravings and addictive behaviors.
|
|
|
TODAY'S TOP VITAL
|
$400 Billion |
Novo Nordisk is now a $400 billion company thanks to its drugs Wegovy and Ozempic.
|
|
|
|
|
